

Erratum to: Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study

Fumihiko Koiwa¹ · Akira Terao²

Published online: 10 November 2016
© Japanese Society of Nephrology 2016

Erratum to: Clin Exp Nephrol DOI 10.1007/s10157-016-1299-z

In the original publication of this paper, the second sentence of Fig. 3 is incorrectly published as:

The mean serum phosphorus levels were significantly higher in all the PA21 groups in all the time-points after administering the PA21 dose (all $P < 0.001$, one-sample t test).

The corrected sentence is given below:

The mean serum phosphorus levels were significantly lower in all the PA21 groups at all the time-points after administering the PA21 dose (all $P < 0.001$, one-sample t test).

The online version of the original article can be found under doi:[10.1007/s10157-016-1299-z](https://doi.org/10.1007/s10157-016-1299-z).

✉ Fumihiko Koiwa
koiwa-f@med.showa-u.ac.jp

¹ Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501, Japan

² Biostatistics, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Japan